India rejects Bayer Nexavar CL appeal
This article was originally published in Scrip
India's apex court recently dismissed Bayer's plea in the high profile Nexavar (sorafenib tosylate) compulsory licensing litigation, but the case hearing appears yet again to have touched upon the delicate issue of R&D spends along the way.
You may also be interested in...
Bayer is battling Natco in another high-profile infringement suit in India, this time pertaining to its anticancer Stivarga (regorafenib). The case has many legs and is to be re-heard by a single judge on the orders of a division bench.
Natco has launched a cut-price version of sacubitril/valsartan (Novartis' Entresto) on the Indian market and is also believed to have opposed the patent for the heart failure therapy.
Humanitarian group MSF says India is facing “pincer-like pressure” to relax its strict patent laws in order to conclude free trade deals in Europe and Asia, and is calling on New Delhi to stand firm.